Experts & Opinions
Should Chronic HCV Patients Wait for Promising Therapies?
In the June/July issue of AGA Perspectives, our point/counterpoint pieces discuss whether patients with hepatitis C virus should be treated now or wait for promising new drugs.
Donald Jensen, MD, and Archita Desai, MD, say that waiting for future therapies risks missing a window of opportunity for successful viral eradication with currently available therapy. In a counterpoint to their article, Gregory Everson, MD, states, “Unlike Beckett’s Godot, the new DAAs are truly coming, and soon. I would suggest that the patient who can wait, and is willing to wait, should consider waiting.”
We want to hear from you. Weigh in on the discussion online with our GI community.
Is Superman* Dead?: Should Work-Hour Limitations Apply toAttending Physicians, and Not Just Trainees?
- Concepts in Drug-Induced Liver Disease
- IL28B Genotyping in the Management of Chronic HCV Infection
- The Hepatologist’s Role in Prescribing Therapy for HCC
- Should We Routinely Do Liver Biopsy in NAFLD Patients?
Visit Our Blog
AGA has launched the AGA Washington Insider, a policy blog for GIs to provide regular updates for members on the activities occurring in Washington and on Capitol Hill.
You can receive an e-mail whenever the blog is updated by entering your address in the e-mail subscription field on the right side of the blog page. (You will be prompted to create an account with WordPress, which hosts the blog. It is a quick process.)
Publish with AGA
Learn how to electronically submit your research for publication in AGA’s premier journals, Gastroenterology and Clinical Gastroenterology and Hepatology, and your abstracts for consideration for presentation at DDW® and inquire about book publishing opportunities with the AGA Institute Press.